Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
| Autor: | Jawhar, Mohamad, Naumann, Nicole, Schwaab, Juliana, Baurmann, Herrad, Casper, Jochen, Dang, Tu-Anh, Dietze, Lutz, Döhner, Konstanze, Hänel, Annette, Lathan, Bernd, Link, Hartmut, Lotfi, Sina, Maywald, Ole, Mielke, Stephan, Müller, Lothar, Platzbecker, Uwe, Prümmer, Otto, Thomssen, Henrike, Töpelt, Karin, Panse, Jens |
|---|---|
| Předmět: |
DRUG therapy
IMATINIB LYMPHOCYTIC leukemia MYELOID leukemia EOSINOPHILIA HEMATOPOIETIC stem cell transplantation CELL receptors CHROMOSOME abnormalities CLINICAL trials COMPARATIVE studies GENES LONGITUDINAL method RESEARCH methodology MEDICAL cooperation POLYMERASE chain reaction PROGNOSIS RESEARCH SEX distribution SURVIVAL EVALUATION research CHRONIC myeloid leukemia REVERSE transcriptase polymerase chain reaction HEMATOLOGIC malignancies |
| Zdroj: | Annals of Hematology; Sep2017, Vol. 96 Issue 9, p1463-1470, 8p |
| Abstrakt: | We evaluated clinical characteristics and outcome on imatinib of 22 patients with myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB. Median age was 49 years (range 20-80), 91% were male. Fifteen different PDGFRB fusion genes were identified. Eosinophilia was absent in 4/19 (21%) cases and only 11/19 (58%) cases had eosinophils ≥1.5×109/L. On imatinib, 17/17 (100%) patients in chronic phase achieved complete hematologic remission after median 2 months (range 0-13). Complete cytogenetic remission and/or complete molecular remission by RT-PCR were achieved in 12/13 (92%) and 12/14 patients (86%) after median 10 (range 3-34) and 19 months (range 7-110), respectively. In patients with blast phase (myeloid, n = 2; lymphoid, n = 3), treatment included combinations of imatinib (n = 5), intensive chemotherapy (n = 3), and/or allogeneic stem cell transplantation (n = 3). All 3 transplanted patients (complex karyotype, n = 2) experienced early relapse. Initially, patients were treated with imatinib 400 mg/day (n = 15) or 100 mg/day (n = 7), the dose was reduced from 400 mg/day to 100 mg/day during follow-up in 9 patients. After a median treatment of 71 months (range 1-135), the 5-year survival rate was 83%; 4/22 (18%) patients died (chronic phase; n = 2; blast phase, n = 2) due to progression (n = 3) or comorbidity while in remission (n = 1). Of note, 3/4 patients had a complex karyotype. In summary, the most important characteristics of myeloid/lymphoid neoplasms with rearrangement of PDGFRB include (a) male predominance, (b) frequent lack of hypereosinophilia, [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink